Announcements Trials
Browse Landscape

Phase

Phase 3 14Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 11NIH 3NETWORK 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

Cisplatin 118Radiotherapy 114Cyclophosphamide 93Paclitaxel 84Gemcitabine 74Carboplatin 67Filgrastim 60Doxorubicin 57Vincristine 56Etoposide 56Docetaxel 56Fluorouracil 51Cytarabine 41Prednisone 40Methotrexate 40Leucovorin 39Dexamethasone 37Capecitabine 36Irinotecan 35Rituximab 29Oxaliplatin 28Granulocyte Colony-Stimulating Factor 27Cetuximab 26Bevacizumab 26durvalumab 24Temozolomide 24Radiotherapy, Intensity-Modulated 24Peripheral Blood Stem Cell Transplantation 24Magnetic Resonance Spectroscopy 24Surgical Procedures, Operative 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × Flutamide × Clear all
NCT00528866 2019-04-24

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Radiation Therapy Oncology Group

Phase 2 Completed
80 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

NCT00028769 2013-07-16

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

SWOG Cancer Research Network

Phase 2 Completed
41 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡